

CARDIOVASCULAR RISK FACTORS AND THE IMPACT ON PROGNOSIS IN PATIENTS WITH CHRONIC KIDNEY DISEASE SECONDARY TO AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

José Luis Gorriz¹, David Arroyo², Luis D'Marco¹, Roser Torra³, Patricia Tomás¹, María Jesús Puchades¹, Nayara Panizo¹, Jonay Pantoja⁴, Marco Montomoli¹, José Luis Llisterrí⁵, Vicente Pallares-Carratalá⁶, José Manuel Valdivielso⁷.

Supplemental Table 1. Comparison between controls, ADPKD patients and patients with CKD from other etiologies. The first "p" value corresponds to the comparison between the three groups and the second value corresponds to the comparison between ADPKD and patients with CKD from other etiologies (CKD stages 3, 4 and 5 not on dialysis).

	Controls n=498 (28.4%)	ADPKD n=132 (7.5%)	CKDoe n=1121 (64.1%)	P Comparison three groups	P ADPKD vs CKDoe
Weight (Kg)	76.00±14.65	76.85±14.86	76.88±14.47	NS	NS
Waist circumference (cm)	95.90±10.86	96.18±11.11	98.09±12.14	0.001	NS
Familial history of CVD	58 (11.6)	14 (10.6)	94 (8.4)	NS	NS
Macroalbuminuria	0 (0.0%)	18 (21.7%)	257 (33.8%)	<0.001	<0.001
Total cholesterol (mg/dL)	204.41±35.63	181.80±37.37	187.39±37.19	<0.001	NS
HDL-cholesterol (mg/dL)	54.36±15.38	49.70±13.52	51.69±15.32	0.001	NS
LDL-cholesterol (mg/dL)	128.73±32.74	106.57±32.26	109.73±32.39	<0.001	NS
Triglycerides (mg/dL)	112.32±66.09	127.98±67.17	138.32±72.96	<0.001	NS
Apo A1 (g/L)	1.24±0.11	1.42±0.35	1.58±0.39	NS	NS
Apo B (g/L)	0.80±0.12	0.81±0.18	0.88±0.25	NS	NS
Glucose (mg/dL)	96.20±12.92	93.55±11.67	96.61±13.78	0.045	NS
Total calcium (mg/dL)	9.41±0.43	9.38±0.53	9.40±0.54	NS	NS
Insulin (µU/mL)	5.99±4.86	9.84±6.51	10.51±9.56	<0.001	NS
SBP >140 mmHg	152 (30.5%)	55 (41.7%)	570 (50.5%)	<0.001	NS
DBP >90 mmHg	70 (14.0%)	34 (25.8%)	231 (20.5%)	0.001	NS
SBP >140 + DBP <90 mmHg	102 (20.4%)	33 (25.0%)	409 (36.3%)	<0.001	0.036

SBP >140 + DBP >90 mmHg	60 (12.0%)	28 (21.2%)	196 (17.4%)	<0.001	0.04
Overweight (BMI 25.1-30 Kg/m²)	236 (47.3%)	58 (43.9%)	483 (42.8%)	NS	NS
Target LDL-cholesterol	349 (80.4%)	59 (50.0%)	390 (39.8%)	<0.001	0.022

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CKDoe, CKD of etiologies other than ADPKD; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; NS, not statistically significant; SBP, systolic blood pressure.

Supplemental table 2. Comparison of treatment between controls, ADPKD patients and patients with CKD from other etiologies. The first "p" value corresponds to the comparison between the three groups and the second value corresponds to the comparison between ADPKD and patients with CKD from other etiologies (CKD stages 3, 4 and 5 not on dialysis).

	Controls n=498 (28.4%)	ADPKD n=132 (7.5%)	CKDoe n=1121 (64.1%)	P Comparison three groups	P ADPKD vs CKDoe
treatments	158 (31.7%)	125 (94.7%)	1037 (91.9%)	<0.001	NS
RAAS blockade	122 (24.4%)	103 (78.1%)	869 (76.2%)	<0.001	NS
ACE inhibitors	41 (8.2%)	41 (31.1%)	393 (34.8%)	<0.001	NS
Angiotensin II receptor blockers	83 (16.6%)	72 (54.5%)	597 (52.9%)	<0.001	NS
Calcium channel blockers	43 (8.6%)	46 (34.8%)	381 (33.8%)	<0.001	NS
Diuretics	34 (6.8%)	50 (37.9%)	518 (45.9%)	<0.001	NS
Alfa blockers	14 (2.8%)	21 (15.9%)	195 (17.3%)	<0.001	NS
Beta blockers	20 (4.0%)	17 (12.9%)	167 (14.8%)	<0.001	NS
Fibrates	11 (2.2%)	3 (2.3%)	67 (5.9%)	0.002	NS
Statin treatment	103 (20.6%)	76 (57.6%)	677 (60.0%)	<0.001	NS
Ezetimibe	6 (1.2%)	3 (2.3%)	52 (4.6%)	0.002	NS
Anti-aggregation	28 (5.6%)	4 (3.0%)	157 (13.9%)	<0.001	<0.001
Anticoagulation	2 (0.4%)	1 (0.8%)	41 (3.6%)	<0.001	NS

Erythropoiesis stimulating agents	0 (0%)	100 (44.4%)	562 (35.1%)	<0.001	NS
--	--------	-------------	-------------	--------	----

Abbreviations: ACE, angiotensin-converting enzyme; ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CKDoe, CKD of etiologies other than ADPKD; NS, not statistically significant; RAAS, renin-angiotensin-aldosterone system; ESA: erythropoiesis stimulating agents.

Supplemental Table 3. Comparison between controls and ADPKD patients with stage 3 CKD.

	Controls n=498 (89.7%)	ADPKD stage 3 CKD n=57 (10.3%)	p
Weight (Kg)	76.00±14.65	78.21±14.90	NS
BMI (Kg/m²)	27.82±4.40	28.27±5.14	NS
Waist circumference (cm)	95.90±10.86	97.14±10.73	NS
Active smoking	100 (20.0%)	16 (28.0%)	NS
Atrial fibrillation	1 (0.2%)	0 (0.0%)	NS
Apo A1 (g/L)	1.24±0.11	1.68±0.28	NS
Apo B (g/L)	0.80±0.12	0.86±0.12	NS
Glucose (mg/dL)	96.20±12.92	93.78±9.89	NS
Insuline (μU/mL)	5.99±4.86	10.17±4.54	NS
Total calcium (mg/dL)	9.41±0.43	9.41±0.49	NS
Phosphate (mg/dL)	3.46±0.52	3.59±0.49	NS
25-hydroxi-vitamin D (ng/mL)	20.58±8.39	18.39±10.04	NS
SBP (mmHg)	132.45±17.44	137.00±20.20	NS
SBP >140 mmHg	152 (30.5%)	20 (35.1%)	NS
DBP >90 mmHg	70 (14%)	12 (21.1%)	NS
SBP >140 + DBP <90 mmHg	102 (20.4%)	12 (21.1%)	NS
SBP >140 + DBP >90 mmHg	60 (12.0%)	10 (17.5%)	NS

Obesity (BMI >30 Kg/m²)	131 (26.3%)	19 (33.3%)	NS
IMT (mm)	0.70±0.14	0.69±0.13	NS
Pathologic ABI (<0.9 or >1.4)	62 (12.4%)	8 (14.0%)	NS
Ischemic ABI (<0.9)	56 (11.4%)	7 (12.5%)	NS
Plaque presence	248 (49.7%)	31 (54.4%)	NS
Beta blockers	20 (4.0%)	4 (7.0%)	NS
Fibrates	11 (2.2%)	1 (1.8%)	NS
Ezetimibe	6 (1.2%)	1 (1.8%)	NS
Antiaggregating	28 (5.6%)	2 (3.5%)	NS
Anticoagulation	2 (0.4%)	0 (0.0%)	NS


Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CKDoe, CKD of etiologies other than ADPKD; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; NS, not statistically significant; SBP, systolic blood pressure.

Supplemental Table 4. Comparison the treatment between controls and ADPKD patients with stage 3 CKD.

Treatment	Controls n=498 (89.7%)	ADPKD stage 3 CKD n=57 (10.3%)	p
Statin treatment	103 (20.6%)	34 (59.6%)	<0.001
Antihypertensive treatment	158 (31.7%)	53 (93.0%)	<0.001
RAAS blockade	122 (24.4%)	48 (84.2%)	<0.001
ACE inhibitors	41 (8.2%)	20 (35.1%)	<0.001
Angiotensin II receptor blockers	83 (16.6%)	32 (56.1%)	<0.001
Calcium channel blockers	43 (8.6%)	15 (26.3%)	<0.001
Diuretics	34 (6.8%)	21 (36.8%)	<0.001
Alfa blockers	14 (2.8%)	7 (12.3%)	<0.001

Abbreviations: ACE, angiotensin-converting enzyme; ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CKDoe, CKD of etiologies other than ADPKD; NS, not statistically significant; RAAS, renin-angiotensin-aldosterone system; ESA: erythropoiesis stimulating agents.

Supplemental Figure 1. Control rates of cardiovascular risk factors: controls vs. ADPKD vs. CKD of other etiologies.



Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; CKDoe, CKD of etiologies other than ADPKD. * Statistically significant differences.